Domino Integrated Solutions
From its position as a leading innovator of technologies that aid product traceability, Domino's Integrated Solutions Group, part of Domino Printing Sciences Plc, is ideally placed to understand the implications of integrating new methods and technologies into existing manufacturing processes. Domino offers modular and scalable Radio Frequency Identification (RFID) systems that provide immediate cost benefit and enable customers to avoid unnecessary costs associated with RFID implementation programmes.
The successful integration of RFID and its inter-operability with common alpha/numeric and 2D symbologies such as Data Matrix and other barcodes is central to Domino's total systems approach. By linking coding platforms from primary packages to secondary cases to tertiary pallets, and from laser marking to ink jet coding and RFID, Domino can improve the accuracy and reliability of product data that provides customers with the opportunity to seek real business improvement.
With a strong systems approach, Domino can incorporate RFID into total turnkey coding solutions, which can be fully integrated within a manufacturing environment. Domino's open-platform approach to RFID ensures that the company's systems are compatible with RFID innovation, and that the most appropriate and effective technology is available to customers.
Working with customers from an initial concept testing stage through to full implementation of in-line automated RFID systems, the Domino Systems Integration Group comprise the necessary technical and project management resources to help ensure the correct RFID and traceability technologies are employed. Domino offers a full project appraisal option, analysing current activities and planning the migration and application choice in a planned, cost-effective and timely fashion to assist in project planning and implementation.
Domino Printing Sciences Plc is a global provider of ink jet and laser technologies, offering total printing and coding solutions.
For further information, please visit: www.domino-printing.com
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.